IL295958A - Molecules processed by protease - Google Patents

Molecules processed by protease

Info

Publication number
IL295958A
IL295958A IL295958A IL29595822A IL295958A IL 295958 A IL295958 A IL 295958A IL 295958 A IL295958 A IL 295958A IL 29595822 A IL29595822 A IL 29595822A IL 295958 A IL295958 A IL 295958A
Authority
IL
Israel
Prior art keywords
immunoglobulin
protein
protease
constant region
tandem
Prior art date
Application number
IL295958A
Other languages
English (en)
Hebrew (he)
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of IL295958A publication Critical patent/IL295958A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL295958A 2020-03-05 2021-03-05 Molecules processed by protease IL295958A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20305233 2020-03-05
PCT/EP2021/055673 WO2021176090A1 (en) 2020-03-05 2021-03-05 Protease-processed molecules

Publications (1)

Publication Number Publication Date
IL295958A true IL295958A (en) 2022-10-01

Family

ID=71096648

Family Applications (1)

Application Number Title Priority Date Filing Date
IL295958A IL295958A (en) 2020-03-05 2021-03-05 Molecules processed by protease

Country Status (12)

Country Link
US (1) US20230279151A1 (ko)
EP (1) EP4114865A1 (ko)
JP (1) JP2023516380A (ko)
KR (1) KR20220150345A (ko)
CN (1) CN115210265A (ko)
AU (1) AU2021231327A1 (ko)
BR (1) BR112022017542A2 (ko)
CA (1) CA3170452A1 (ko)
IL (1) IL295958A (ko)
MX (1) MX2022010958A (ko)
TW (1) TW202146463A (ko)
WO (1) WO2021176090A1 (ko)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
CA2807278A1 (en) * 2010-08-24 2012-03-01 F. Hoffmann - La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
CA2836468C (en) * 2011-05-17 2021-05-04 The Rockefeller University Human immunodeficiency virus neutralizing antibodies and methods of use thereof
WO2013006544A1 (en) * 2011-07-06 2013-01-10 Medimmune, Llc Methods for making multimeric polypeptides
KR101963230B1 (ko) * 2011-12-26 2019-03-29 삼성전자주식회사 복수개의 단일 항체를 포함하는 단백질 복합체
MX2017003847A (es) * 2014-09-25 2017-12-15 Amgen Inc Proteinas biespecificas activables por proteasas.
EA201892312A1 (ru) 2017-03-17 2019-04-30 Санофи Триспецифические и/или тривалентные связывающие белки

Also Published As

Publication number Publication date
EP4114865A1 (en) 2023-01-11
BR112022017542A2 (pt) 2022-10-18
KR20220150345A (ko) 2022-11-10
US20230279151A1 (en) 2023-09-07
JP2023516380A (ja) 2023-04-19
CA3170452A1 (en) 2021-09-10
MX2022010958A (es) 2022-10-07
WO2021176090A1 (en) 2021-09-10
AU2021231327A1 (en) 2022-10-27
TW202146463A (zh) 2021-12-16
CN115210265A (zh) 2022-10-18

Similar Documents

Publication Publication Date Title
US20230064544A1 (en) Anti-ctla4 monoclonal antibody or its antigen binding fragments, pharmaceutical compositions and uses
JP2022536898A (ja) 新規ｉｌ－１５プロドラッグおよびその使用方法
US20210388105A1 (en) Novel anti-cd39 antibodies
KR102247704B1 (ko) 항 pd-1/항 her2 천연항체 구조 형태의 헤테로다이머 계의 이중특이성 항체 및 그 제조방법
CN109535253B (zh) 新型抗cd19抗体
JP7352973B2 (ja) 二重特異性抗体及びその使用
TWI716059B (zh) 經改良的促凝血抗體
KR20200004292A (ko) 항 인터페론 감마 항체 및 그의 용도
KR20200120648A (ko) 항pd-1/항her2 천연항체 구조 헤테로다이머계의 이중특이성 항체 및 그 제조방법
WO2014076292A1 (en) Recombinant bispecific antibody binding to cd20 and cd95
JP2022550243A (ja) 抗ｐｄ－１抗体及びその使用
CN115052894A (zh) 靶向cd39和tgfbeta的新型缀合物分子
WO2019068758A1 (en) MODIFIED CYSTEINE MOLECULES BINDING TO ANTIGEN
CN116348492A (zh) 四面体抗体
IL295958A (en) Molecules processed by protease
CA3023088A1 (en) Novel anti-tnfrsf21 antibodies and methods of use
CN116391041A (zh) 一种含抗结缔组织生长因子抗体的药物组合物
WO2024111657A1 (ja) タンパク質の製造方法
WO2024113099A1 (en) Protease cleavable recombinant bispecific antibodies and compositions and uses thereof
WO2024109914A1 (zh) 一种包含特异性结合hgfr和egfr的双特异性抗体的药物组合物
WO2024131835A1 (en) Ligand-cytotoxicity drug conjugates and pharmaceutical uses thereof
KR20230154020A (ko) 클라우딘-6에 대한 항체 및 이의 용도
CN117597362A (zh) 抗紧密连接蛋白-6的抗体及其用途
WO2024023273A1 (en) Bispecific anti-c-kit and anti-cd203c antigen-binding molecules and uses thereof
WO2023242320A1 (en) Compositions comprising antibodies that bind gamma-delta t cell receptors